We observed that amplification of SKP2 frequently occurs in various cancers, including sarcoma, urothelial or bladder cancer, lung cancer, gastric cancer, metastatic prostate cancer, and prostate adenocarcinoma with a range from about 12% to 6% (Fig. 7D). Here, SKP2 is linked to prostate adenocarcinoma.